Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9

Stine Braendegaard Winther; Pia Österlund; Ake Berglund; Bengt Glimelius; Camilla Qvortrup; Halfdan Sorbye; Per Pfeiffer; Acad Geriatric Canc Res AgeCare

doi:10.1186/s12885-017-3526-8

Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9

Stine Braendegaard Winther, Pia Österlund, Ake Berglund, Bengt Glimelius, Camilla Qvortrup, Halfdan Sorbye, Per Pfeiffer, Acad Geriatric Canc Res AgeCare

Research output: Contribution to journal › Article › Scientific › peer-review

Original language	English
Article number	548
Journal	BMC Cancer
Volume	17
Number of pages	7
ISSN	1471-2407
DOIs	https://doi.org/10.1186/s12885-017-3526-8
Publication status	Published - 16 Aug 2017
MoE publication type	A1 Journal article-refereed

Fields of Science

Randomized phase II
Non-intensive
SOX
IRIS
Oral
Geriatric assessment
Metastatic colorectal cancer
COOPERATIVE-ONCOLOGY-GROUP
ELDERLY-PATIENTS
PHASE-3 TRIAL
OPEN-LABEL
GERIATRIC ASSESSMENT
PALLIATIVE CHEMOTHERAPY
INTERNATIONAL-SOCIETY
1ST-LINE TREATMENT
YOUNGER PATIENTS
SCREENING TOOLS
3122 Cancers

Access to Document

10.1186/s12885-017-3526-8

Randomized study comparingFinal published version, 496 KBLicence: CC BY

Cite this

Winther, S. B., Österlund, P., Berglund, A., Glimelius, B., Qvortrup, C., Sorbye, H., Pfeiffer, P., & Acad Geriatric Canc Res AgeCare (2017). Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9. BMC Cancer, 17, Article 548. https://doi.org/10.1186/s12885-017-3526-8

@article{1f24c1f4500e4d87bb3151636d14de9a,

title = "Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9",

keywords = "Randomized phase II, Non-intensive, SOX, IRIS, Oral, Geriatric assessment, Metastatic colorectal cancer, COOPERATIVE-ONCOLOGY-GROUP, ELDERLY-PATIENTS, PHASE-3 TRIAL, OPEN-LABEL, GERIATRIC ASSESSMENT, PALLIATIVE CHEMOTHERAPY, INTERNATIONAL-SOCIETY, 1ST-LINE TREATMENT, YOUNGER PATIENTS, SCREENING TOOLS, 3122 Cancers",

author = "Winther, {Stine Braendegaard} and Pia {\"O}sterlund and Ake Berglund and Bengt Glimelius and Camilla Qvortrup and Halfdan Sorbye and Per Pfeiffer and {Acad Geriatric Canc Res AgeCare}",

year = "2017",

month = aug,

day = "16",

doi = "10.1186/s12885-017-3526-8",

language = "English",

volume = "17",

journal = "BMC Cancer",

issn = "1471-2407",

publisher = "BMC",

}

Winther, SB, Österlund, P, Berglund, A, Glimelius, B, Qvortrup, C, Sorbye, H, Pfeiffer, P & Acad Geriatric Canc Res AgeCare 2017, 'Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9', BMC Cancer, vol. 17, 548. https://doi.org/10.1186/s12885-017-3526-8

Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9. / Winther, Stine Braendegaard; Österlund, Pia; Berglund, Ake et al.
In: BMC Cancer, Vol. 17, 548, 16.08.2017.

Research output: Contribution to journal › Article › Scientific › peer-review

TY - JOUR

T1 - Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer

T2 - NORDIC 9

AU - Winther, Stine Braendegaard

AU - Österlund, Pia

AU - Berglund, Ake

AU - Glimelius, Bengt

AU - Qvortrup, Camilla

AU - Sorbye, Halfdan

AU - Pfeiffer, Per

AU - Acad Geriatric Canc Res AgeCare

PY - 2017/8/16

Y1 - 2017/8/16

KW - Randomized phase II

KW - Non-intensive

KW - SOX

KW - IRIS

KW - Oral

KW - Geriatric assessment

KW - Metastatic colorectal cancer

KW - COOPERATIVE-ONCOLOGY-GROUP

KW - ELDERLY-PATIENTS

KW - PHASE-3 TRIAL

KW - OPEN-LABEL

KW - GERIATRIC ASSESSMENT

KW - PALLIATIVE CHEMOTHERAPY

KW - INTERNATIONAL-SOCIETY

KW - 1ST-LINE TREATMENT

KW - YOUNGER PATIENTS

KW - SCREENING TOOLS

KW - 3122 Cancers

U2 - 10.1186/s12885-017-3526-8

DO - 10.1186/s12885-017-3526-8

M3 - Article

SN - 1471-2407

VL - 17

JO - BMC Cancer

JF - BMC Cancer

M1 - 548

ER -

Winther SB, Österlund P, Berglund A, Glimelius B, Qvortrup C, Sorbye H et al. Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9. BMC Cancer. 2017 Aug 16;17:548. doi: 10.1186/s12885-017-3526-8